News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIOGUARD® products employ Nimbus Technology and is licensed to: Derma Sciences, Inc.
In April, 2007, we entered into a license agreement with Derma Sciences Inc. for NIMBUS treatment of select substrates used in traditional wound care. In February, 2009 we received FDA market clearance for the NIMBUS gauze wound dressing licensed to Derma Sciences and in June, 2009 Derma Sciences reported first commercial sale of a product, BIOGUARD® wound dressings, employing our NIMBUS technology. Derma Sciences is marketing and selling the BIOGUARD product to the professional health care market including acute care hospitals, extended care hospitals, nursing homes, and wound care centers. In July 2012, we entered into a new license agreement with Derma Sciences that grants Derma a worldwide (except for India) exclusive license to our NIMBUS treatment of traditional wound dressings in return for $1.3 million in upfront payment, additional milestone payments and ongoing royalty payments.
Here are some of the BIOGUARD® products:
Websites carrying BIOGUARD® products:
http://www.hightidehealth.com/bioguard-barrier-dressings.html
http://www.medline.com/product/SPONGEBIOGUARD-ANTIMICROBIAL-12PL-4X4/Sponges/Z05-PF31309
http://www.dermasciences.com/bioguard-products
http://www.ebay.com/sch/sis.html?_nkw=Bioguard+Gauze+Bandages+97322+Lot+of+6+large+Rolls
http://www.woundsource.com/product/bioguard-barrier-dressings-conforming-bandages
http://www.vitalitymedical.com/bioguard-barrier-dressings.html
http://www.expressmed.com/product/wound-dressings/73959-63151/bioguard-gauze-roll.html
|
Followers
|
18
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
732
|
|
Created
|
03/15/05
|
Type
|
Free
|
| Moderators | |||
QUICK-MED TECHNOLOGIES INC.
http://www.quickmedtech.com/
F.D.A./E.P.A APPROVED/10+ PATENTS + TRADEMARKS
(2019-2030 Expiree Dates)
Competitor Patents Expired
CONTINUOS FUNDING from U.S. ARMY
PARTNERS
AVERY DENNISON of the NYSE @ $50+
BASF of the QX @ $90+
DERMA SCIENCE of the NASDAQ @ $8+
WEXLER, DORIS, POLARTEC, BIOSARA
MEDLINE (Private) $5 Billion+ Annual Sales
$15 BILLION MARKET
MARKET CAP $1,500,000
SHARE STRUCTURE
100,000,000 A/S 37,300,000 O/S
****19,000,000 FLOAT****
18,000,000 RESTRICTED
Quick-Med Technologies, Inc is a life sciences company focused on developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets.
The Company’s four core technologies are:
NIMBUS®: a family of advanced polymers bioengineered for antimicrobial, hemostatic, and other properties that can be used in a wide range of medical device applications including wound dressings, medical textiles, catheters, tubing, films and coatings.
Stay Fresh®: a unique chemical formulation for textiles with a durable antimicrobial agent effective against an array of bacteria even after numerous laundering cycles.
NimbuDerm™: a novel copolymer for application as a persistent hand sanitizer with long lasting protection against germs.
MultiStat®: a family of advanced patented methods and compounds shown to be effective in skin therapy applications.
Quick-Med Technologies, Inc. is a publicly-traded company listed under the symbol "QMDT" on the OTCQB listings of the OTC marketplace.
Dr. Bernd Liesenfeld
President
Dr. Liesenfeld joined Quick-Med in 2004 and led the development of the NIMBUS® technology used in the Bioguard line of products licensed to Derma Sciences. He has been involved in all aspects of commercializing Quick-Med's antimicrobial technologies, including biochemistry, biosafety, regulatory and production development. Dr. Liesenfeld also led the Quick-Med team that received the top industrial research prize at the 2011 Wound Healing Society meeting for U.S. Army-sponsored research that showed improved wound healing in an animal model of vesicant injury using an advanced multi-feature NIMBUS dressing. Dr. Liesenfeld received a Ph.D. in Materials Science and Engineering from the University of Florida and holds a Bachelor's degree in Mechanical Engineering and Management from the University of Vermont.
Paul Jenssen
Chief Financial Officer
Mr. Jenssen has over 35 years of experience in strategic planning, process improvement, finance and accounting. He started his career at Deloitte Touche (1978-1984) before becoming Treasurer at Associated Press (1984-1998). In addition to working as a consultant since 1998, he was the CFO, COO and a Senior Managing Director at Rothschild North America investment bank (1998-2006). From 2006 until the present, Mr. Jenssen was the President of Jenssen Consulting, a business involved in providing strategic planning, process improvement, finance and accounting related services. Mr. Jenssen is a CPA, has an MBA from Columbia University in New York and has held several securities licenses.
Dr. William Toreki
Vice President, Research & Development
Dr. Toreki joined the Company in 2002 as QMT’s Chief Scientist and is the lead inventor on ten of the Company’s patents. Dr. Toreki received a Ph.D. in Polymer and Analytical Chemistry in 1988 from The University of Florida, and earned a Bachelor’s degree in Chemistry from The University of Delaware in 1982.
Dr. Toreki is an experienced inventor with 20 granted US patents to his credit, and during his tenure at QMT, he has been responsible for the development of three new antimicrobial platforms, including the adaptation of orphaned technology into the new Stay Fresh® antimicrobial system, the NIMBUS® antimicrobial technology that forms the core technology of the company, and the NimbuDerm™ antimicrobial skin protection formulation
http://www.quickmedtech.com/company/board-of-directorsboard-of-directors
Quick-Med’s patented technology, NIMBUS® is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS® received de Novo FDA clearance in June 2009 and has been commercialized in traditional wound care applications. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
NIMBUS® is based on non-toxic, long chain polymers with high charge density that provide superior efficacy via a physical action on microbes. By destroying bacteria at the cellular level, NIMBUS® eliminates the risk of developing drug resistance. The technology is highly effective against a multitude of bacteria, including Methicillin-resistant Staphylococcus aureus ("MRSA") and Vancomycin-resistant Enterococcus ("VRE"), two of the most significant antibiotic-resistant organisms responsible for hospital infections.
Unlike any other microbicide on the market today, this cost-effective technology works by creating a non-leaching, permanent bond with a multitude of substrates and is less than 10% the cost of silver-based antimicrobials. NIMBUS® technology enhances the value of treated products and brings dependable, durable and safe antimicrobial protection at extraordinary value—only pennies per product.
Quick-Med has entered licensing agreements with leading wound care companies for NIMBUS® technology with their products. The Company is targeting additional partnerships to apply the NIMBUS® technology in advanced wound care products, catheters, incontinence products and other medical devices
Stay Fresh® Antimicrobial
Stay Fresh® Antimicrobial is a breakthrough antimicrobial textile treatment technology under development for a broad range of applications, including healthcare textiles, commercial uniforms and essential wear.
Stay Fresh Antimicrobial is an EPA-registered product thatoffers material protection for a wide variety of applications, for which a range of solution concentrations are available. The range of application varies widely by intended use, durability requirement, and substrate material.
Stay Fresh Antimicrobial has excellent durability. It imparts durable antimicrobial activity to the surface of a wide variety of substrates. Stay Fresh Antimicrobial suppresses the growth of algae, mold, mildew, fungi and bacteria which cause unpleasant odors, discoloration, staining, deterioration and corrosion.
Stay Fresh® Skin Fold Management Textile
The Stay Fresh Skin Fold Management Textile is an FDA-regulated skin protectant product that provides moisture management to keep skin dry and reduce friction in skin folds and other skin-to-skin contact areas. The Stay Fresh Skin Fold Management Textile contains hydrogen peroxide, which reduces bacterial populations in the fabric. The Stay Fresh Skin Fold Management Textile is a single use product that is custom cut to the desired size from a multiuse roll.
The Stay Fresh Skin Fold Management Textile has been shown to be effective against the following organisms after five days of simulated use conditions, using standard in vitro microbiological methods
NimbuDerm™ is a novel copolymer under development to deliver a breakthrough in hand-hygiene technology. The persistent hand sanitizer has achieved proof-of-principle in providing extraordinarily long lasting antimicrobial protection that is safe, effective, and instant. It reduces bacteria on hands and prevents infections before they develop, contributing to good health, minimizing cost and risk, and saving lives.
NimbuDerm™ has been formulated as a skin-soothing composition, and unlike the alcohol based skin sanitizers available today, it does not lose its efficacy soon after application. NimbuDerm™ can be removed with a soap and water wash, but because it remains active for eight hours, it doesn’t need to be re-applied after every activity. Thus it is kind to the skin.
NimbuDerm™ is effective against MRSA and VRE, two resistant bacterial strains, as well an extensive list of bacteria commonly associated with infections. It acts immediately, reducing the invasive population by 99.99% and has been shown to be 99.9% effective against viral contamination as well.
Like other marketed hand sanitizers, NimbuDerm™ provides rapid protection but it is differentiated by imparting sustained protection for up to eight hours
MultiStat® is Quick-Med’s family of patented compounds and technologies, Matrix Metalloproteinase Inhibitors (MMPIs), that modern research has shown to play a key role in numerous skins conditions, and boasts a broad spectrum of uses including cosmetic and pharmaceutical (consumer, medical, and military).
MultiStat® has demonstrated clinical success in improving the appearance of fine lines and wrinkles resulting from natural aging or sun damage, and has significant benefits in other skin conditions, such as roughness or redness.
MultiStat® is currently an active ingredient in commercially available anti-aging creams.
Ilomastat, a MultiStat®-family compound, is one of the most powerful synthetic MMPI compounds in existence. It has been shown in laboratory testing and in clinical animal models to provide significant protection from vesicant injuries (such as sulfur mustard), and to promote healing after injury in both skin and eyes. The US Army has funded Quick-Med research into the uses of Ilomastat as protective or curative agent against potential terrorist threats from Sulfur Mustard gas, with results demonstrating improved recovery from vesicant eye injury.
